Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/20105
DOI URL: http://dx.doi.org/10.21474/IJAR01/20105

RESEARCH ARTICLE

AMENAMEVIR: A BREAKTHROUGH IN HERPESVIRUS THERAPY

Arisha Salam[1], Kuldeep Verma[2], Sandeep Nair[3] and Abhinesh Nagarajan[4]

1. MD, Senior Resident, Department of Dermatology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair.
2. MD, Assistant Professor, Department of Skin and VD, Government Medical College , Orai
3. MBBS, Department of Dermatology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair.
4. MD, Senior Resident, Department of DVL, Tagore Medical College and Hospital, Chennai.

Manuscript Info

Manuscript History
Received: 20 October 2024
Final Accepted: 23 November 2024
Published: December 2024

Abstract

Amenamevir is a promising antiviral agent with strong activity against herpes simplex virus (HSV) and varicella-zoster virus (VZV). This review article aims to explore its pharmacodynamics, therapeutic potential, and safety profile in detail. Amenamevir functions by inhibiting the viral helicase-primase complex, a crucial step in viral DNA replication, distinguishing it from other antiviral drugs. The article examines the results from clinical trials assessing its efficacy in treating recurrent herpesvirus infections, its pharmacokinetic properties, and its suitability for patients with compromised immune systems. We also discuss the drug's safety and tolerability, identifying common side effects, drug interactions, and contraindications. Furthermore, the review highlights Amenamevir's potential role in managing antiviral resistance and its possible broader applications in the treatment of chronic viral infections. Finally, future directions are outlined, including the exploration of combination therapy and the development of more accessible oral formulations, to optimize the clinical use of Amenamevir.

Introduction:-

Amenamevir is an Oxydiazolephenyl derivative antiviral drug with the trade name of Amenalief used for the treatment of Shingles(Herpes Zoster). It was First approved in Japan for the treatment of Shingles in 2017[1].

The chemical formula of Amenamevir is C24H26N4O5S with a molar mass of 482.56 g·mol−1[1]. [Figure1]

Mechanism of Action:-

Amenamevir functions by inhibiting the helicase-primase complex, a crucial enzyme system required for herpesvirus DNA replication. This complex consists of two proteins, the helicase and primase, which are essential for unwinding the viral DNA and initiating the synthesis of RNA primers for replication. Amenamevir selectively binds to the helicase, disrupting its ability to unwind the viral DNA. As a result, the virus is unable to replicate its genetic material, effectively limiting its ability to propagate within the host. This mechanism of action is distinct from other antiviral agents that target viral polymerases, offering a unique approach to controlling herpesvirus infections, particularly in cases where resistance to conventional treatments may occur.[2]

Corresponding Author:- Abhinesh Nagarajan
Address:- MD, Senior Resident, Department of DVL, Tagore Medical College and Hospital, Chennai.

Application in Dermatology:-[3]

Amenamevir is an antiviral drug used mainly to treat infections caused by the herpes simplex virus (HSV), especially in individuals with weakened immune systems. In dermatology, it is used for managing various skin conditions associated with herpes viruses, such as:

1. Herpes Simplex Virus (HSV) Infections: Amenamevir has proven effectiveness in treating both HSV-1 and HSV-2, which are responsible for oral herpes (cold sores) and genital herpes. It works by inhibiting the replication of the virus, which leads to a reduction in symptoms and accelerates the healing process of affected skin.
2. Herpes Zoster (Shingles): While acyclovir is more commonly used, amenamevir may also be beneficial in treating herpes zoster, which causes painful rashes on areas such as the chest, face, or back. It helps reduce viral activity and alleviate symptoms related to the condition.
3. Prevention of Recurrence: In patients who experience recurrent herpes simplex infections, amenamevir can help reduce the frequency of outbreaks, thus improving the patient‘s overall quality of life and providing relief from recurrent episodes.

This medication is especially useful for individuals with compromised immune systems, such as those with HIV/AIDS or those undergoing organ transplants, as viral infections tend to be more severe and persistent in such cases.

Need of a newer drug:-

Currently, there are several antiviral medications available for the treatment of HSV infections, which can help reduce recurrence and the duration of herpetic lesions. The most commonly used are acyclovir (ACV), valacyclovir, and penciclovir, all of which target viral polymerase and inhibit the replication of HSV genomes. However, these drugs can be less effective for certain clinical manifestations, such as skin lesions, and drug-resistant HSV strains often emerge in both immunocompromised and immunocompetent individuals. As a result, there is a critical need to develop more effective antiviral treatments and novel strategies to address these drug-resistant variants.

Clinical researches:-

1. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster [4]

Amenamevir, a novel Helicase-Primase Inhibitor (HPI), has emerged as a promising treatment option for herpes zoster, which is caused by the varicella-zoster virus (VZV). By targeting the helicase-primase complex, a key enzyme in viral DNA replication, Amenamevir prevents the replication of the virus. Clinical studies have demonstrated that Amenamevir is particularly effective against acyclovir-resistant strains of VZV, providing an important alternative for patients who do not respond to conventional therapies. In fact, one case study reported successful treatment of a patient with herpes zoster caused by acyclovir-resistant VZV, illustrating Amenamevir‘s potential in tackling challenging, resistant infections. Therefore, Amenamevir holds significant promise in the management of herpes zoster, especially for patients who fail to respond to traditional antiviral agents.

2. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies [5]

A series of Phase 1 randomized studies investigated the pharmacokinetics and safety profile of Amenamevir in healthy subjects. The findings revealed that Amenamevir was both well-tolerated and safe at high doses, including single doses up to 2400 mg and multiple doses up to 600 mg per day for 7 days. The pharmacokinetic analysis demonstrated that Amenamevir exhibited non-dose-proportional characteristics, meaning its absorption and metabolism did not increase in direct proportion to the dose. This suggests that the drug maintains consistent therapeutic levels despite variations in dosage. These results support the conclusion that Amenamevir has a manageable safety profile and stable pharmacokinetics, making it a suitable candidate for ongoing clinical use.

3. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers [6]

Several clinical studies have assessed the pharmacokinetic interactions between Amenamevir and various drugs metabolized by the CYP3A enzyme system, including midazolam, cyclosporine, and ritonavir. These studies confirmed that Amenamevir interacts with these substances, affecting their metabolism. Specifically, Amenamevir induced the metabolism of midazolam, which increased its clearance. Conversely, cyclosporine reduced the plasma levels of Amenamevir, while ritonavir inhibited its clearance, even when administered as a single dose. These

findings highlight the importance of considering potential drug-drug interactions when prescribing Amenamevir, especially in patients who are already on medications that affect CYP3A activity. Careful monitoring and possible dose adjustments may be required to optimize treatment outcomes and minimize adverse effects.

4. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of Amenamevir (ASP2151) [7]

Research examining the pharmacokinetics of Amenamevir in individuals with hepatic and renal impairments has provided important insights into its use in these populations. The study on hepatic impairment found that no adjustment to the dosing regimen is necessary for patients with moderate liver dysfunction, indicating that Amenamevir can be used safely in this group. Similarly, the renal impairment study showed that the pharmacokinetics of Amenamevir were not significantly altered by varying levels of renal function. This suggests that no dose reduction is required for patients with renal impairment, making Amenamevir a viable option for patients with compromised kidney function. These findings expand the potential clinical use of Amenamevir, particularly in patients with concurrent hepatic or renal conditions.

5. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults [8]

A series of studies analyzed the potential interactions between Amenamevir and several commonly prescribed drugs, including ketoconazole, rifampicin, midazolam, and warfarin. The results demonstrated that Amenamevir interacts with both ketoconazole and rifampicin due to its role as a substrate for the CYP3A4 enzyme. Ketoconazole, a potent CYP3A4 inhibitor, reduced the clearance of Amenamevir, while rifampicin, a known CYP3A4 inducer, enhanced its clearance. Additionally, as a CYP3A4 inducer, Amenamevir affected the pharmacokinetics of midazolam, leading to increased metabolism and reduced plasma concentrations. However, no significant interaction was observed between Amenamevir and warfarin, indicating that Amenamevir does not impact the metabolism of warfarin through the CYP2C9 enzyme. These findings suggest that clinicians should be cautious when co-administering Amenamevir with CYP3A4 inhibitors or inducers and may need to adjust dosages accordingly.

6. Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers [9]

Further studies have explored the potential pharmacokinetic interactions between Amenamevir and substrates of other cytochrome P450 enzymes, including CYP2C8 and CYP2B6. Specifically, montelukast (a CYP2C8 substrate) and bupropion (a CYP2B6 substrate) were co-administered with Amenamevir to assess any impact on their concentrations. The results showed only minor changes: montelukast levels increased by 22%, while bupropion levels decreased by 16%. These modest alterations suggest that Amenamevir has a minimal effect on the metabolism of these drugs and that dose adjustments are unlikely to be necessary when they are co-prescribed. This finding reinforces Amenamevir's favorable profile in terms of drug interactions, supporting its safe use in combination with other medications metabolized by CYP2C8 and CYP2B6.

Treatment regimen:-

According to Principles and Practices of Infectious Diseases (8^{th} edition, 2015), a dose-finding, placebo-controlled study involving 437 patients with recurrent genital herpes assessed the efficacy of Amenamevir. The study involved administering one of four doses of amenamevir: 100 mg, 200 mg, 400 mg daily for three days, or a single 1200 mg dose. Another group received valacyclovir at 500 mg twice daily for three days. Results showed that recurrent episodes were 1 to 2 days shorter in the amenamevir-treated groups compared to the placebo group. However, only the 1200 mg single-dose group showed a significant difference in the primary endpoint, which was the time to lesion healing, compared to the placebo. The single-dose amenamevir group showed comparable efficacy to the 3-day valacyclovir treatment.[10]

Additionally, a Phase 3, randomized, placebo-controlled study titled A Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes examined the effectiveness of patient-initiated amenamevir 1200 mg within 6 hours of prodromal symptom onset. The study found that the single-dose amenamevir treatment reduced the time to lesion healing compared to placebo, without safety concerns. This suggests that it could be an effective option for treating recurrent genital herpes in patients able to recognize prodromal symptoms.[9]

Side effects:- [10]

The side effects of Amenamevir includes:-

Gastrointestinal side effects:- Patient may experience Nausea, Stomach pains and Diarrheas related problems. These symptoms are generally mild and mostly resolve on it own.

Headache

Dizziness

Fatigue

Allergic reactions:- less common but more severe side effect including Rash, Itching, Swelling and Breathing difficulties.

Jaundice:- In very severe cases yellowish discoloration of eyes and skin may occur due to damage to liver.

Legends To Figures:

Figure 1:- Chemical formula of Amenamevir.



Figure 2:- Mechanism of action of Amenamevir.



UL5, UL8, UL52 HSV -proteins forming a HP (helicase-primase) complex, UL30,UL42-HSV proteins forming a DNA polymarse complex, ICP8 -single-stranded DNA binding proteine

Conclusion:-

Amenamevir offers a promising new approach for managing herpesvirus infections, particularly in patients with recurrent or resistant cases. By targeting the helicase-primase complex, the drug effectively disrupts viral DNA replication, providing an alternative to conventional antiviral therapies. Clinical evidence supports its efficacy, favorable pharmacokinetic profile, and overall safety, positioning Amenamevir as a valuable therapeutic option in both immunocompetent and immunocompromised individuals. As viral resistance to traditional antivirals remains a growing concern, Amenamevir's distinct mechanism of action could play a critical role in future treatment strategies. Ongoing research into its long-term efficacy and potential use in combination therapies will be essential in further defining its place in the clinical management of herpesvirus infections

References:-

1.Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol. 2017 Nov;44(11):1219–27.
2.Shiraki K, Yasumoto S, Toyama N, Fukuda H. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster. Viruses. 2021 Aug 5;13(8):1547.
3.Imashuku S, Ohyashiki JH, Yamada Y, et al. Phase 3 study of Amenamevir in patients with herpes zoster. J Infect Dis. 2017 Oct 1;216(7):862–70.
4.Shiraki K, Yasumoto S, Toyama N, Fukuda H. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster. Viruses. 2021 Aug 5;13(8):1547.
5.Kusawake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, Ohtsu Y, Katashima M. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. Adv Ther. 2017 Dec;34(12):2625–37.
6.Adeloye T, Sahgal O, Puri A, Warrington S, Endo T, Dennison J, Johnston A. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions with Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):844–59. doi: 10.1002/cpdd.586. Epub 2018 Jul 25.
7.Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, Lewand M, Lasseter KC, Marbury TC, Preston RA. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies. Adv Ther. 2017 Dec;34(12):2612–24.
8.Kusawake T, den Adel M, Groenendaal-van de Meent D, Garcia-Hernandez A, Takada A, Kato K, Ohtsu Y, Katashima M. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults. Adv Ther. 2017 Nov;34(11):2466–80.
9.Dennison J, Puri A, Warrington S, Endo T, Adeloye T, Johnston A. Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions with Montelukast and Bupropion in Healthy Volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):860–70.
10.Mandell D, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995.
11.Kawashima M, Imafuku S, Fujio K, Komazaki H. Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Open Forum Infect Dis. 2022 Sep 22;9(10):494.